- Home
- BWIN vs HRMY Comparison
BWIN vs HRMY Comparison
Compare BWIN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWIN
- HRMY
- Stock Information
- Founded
- BWIN 2011
- HRMY 2017
- Country
- BWIN United States
- HRMY United States
- Employees
- BWIN N/A
- HRMY N/A
- Industry
- BWIN Specialty Insurers
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- BWIN Finance
- HRMY Health Care
- Exchange
- BWIN Nasdaq
- HRMY Nasdaq
- Market Cap
- BWIN 2.2B
- HRMY 1.9B
- IPO Year
- BWIN 2019
- HRMY 2020
- Fundamental
- Price
- BWIN $28.80
- HRMY $27.28
- Analyst Decision
- BWIN Buy
- HRMY Strong Buy
- Analyst Count
- BWIN 8
- HRMY 10
- Target Price
- BWIN $44.00
- HRMY $51.30
- AVG Volume (30 Days)
- BWIN 796.6K
- HRMY 1.1M
- Earning Date
- BWIN 11-03-2025
- HRMY 10-28-2025
- Dividend Yield
- BWIN N/A
- HRMY N/A
- EPS Growth
- BWIN N/A
- HRMY 58.41
- EPS
- BWIN N/A
- HRMY 3.10
- Revenue
- BWIN $1,461,046,000.00
- HRMY $772,527,000.00
- Revenue This Year
- BWIN $11.16
- HRMY $20.09
- Revenue Next Year
- BWIN $13.54
- HRMY $16.86
- P/E Ratio
- BWIN N/A
- HRMY $8.81
- Revenue Growth
- BWIN 11.44
- HRMY 17.74
- 52 Week Low
- BWIN $26.33
- HRMY $26.26
- 52 Week High
- BWIN $55.82
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- BWIN 41.25
- HRMY 26.28
- Support Level
- BWIN $26.33
- HRMY $26.26
- Resistance Level
- BWIN $31.15
- HRMY $28.00
- Average True Range (ATR)
- BWIN 1.12
- HRMY 1.02
- MACD
- BWIN -0.04
- HRMY -0.34
- Stochastic Oscillator
- BWIN 42.37
- HRMY 14.68
About BWIN The Baldwin Insurance Group Inc. Class A Common Stock
The Baldwin Insurance Group Inc is a United States-based insurance distribution firm. Its products include Business Insurance, Benefits Consulting, Reinsurance, Specialty MGA, Embedded Insurance., Personal insurance, etc.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.